- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit ...
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0 ™ principles with sustainable design to transform plasma manufacturing
SUMMIT, N.J. , Oct. 21, 2025 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), announced recent data showing that cell-based influenza vaccines offer greater protection in preventing test-confirmed...
In a report released on October 13, Steven Wheen from Jarden maintained a Buy rating on CSL, with a price target of A$298.13. The company’s shares closed yesterday at $131.65.Elevate Your Investing Strategy:...
Bell Potter analyst Thomas Wakim maintained a Hold rating on CSL today and set a price target of A$230.00. The company’s shares closed yesterday at $131.65.Elevate Your Investing Strategy: Take advantage...
UBS analyst Marcus Curley maintained a Buy rating on CSL today and set a price target of A$300.00. The company’s shares closed today at $131.65.Elevate Your Investing Strategy: Take advantage of TipRanks...
In a report released today, Andrew Paine from CLSA maintained a Buy rating on CSL, with a price target of A$275.00. The company’s shares closed last Friday at $130.18.Elevate Your Investing Strategy:...
In a report released today, Marcus Curley from UBS maintained a Buy rating on CSL, with a price target of A$300.00. The company’s shares closed last Monday at $129.44.Elevate Your Investing Strategy:...
In a report released on October 3, from Canaccord Genuity maintained a Hold rating on CSL, with a price target of A$227.50. The company’s shares closed last Friday at $132.43.Elevate Your Investing Strategy:...
In a report released today, Marcus Curley from UBS maintained a Buy rating on CSL, with a price target of A$300.00. The company’s shares closed last Friday at $132.43.Elevate Your Investing Strategy:...